Pancreatic fusocellular sarcoma. The importance of endoscopic ultrasound-guided fine needle aspiration in the differential diagnosis of solid pancreatic tumors

J. Iglesias García1,2, R. Ferreiro1,2, J. Lariño Noia1,2, I. Abdulkader1, M. Álvarez del Castillo1,2, B. Cigarrán2,4, J. Forteza Vila3 and J. E. Domínguez Muñoz1,2

1Gastroenterology Department. 2Foundation for Research in Digestive Diseases, and 3Pathology Department. University Hospital, Santiago de Compostela. A Coruña, Spain. 4Internal Medicine Department. Hospital Virxe da Xunqueira de Cee. A Coruña, Spain

ABSTRACT

In the presence of a pancreatic tumor, the main diagnostic problem is to determine the benign or malignant nature of the lesion, and then to evaluate its resectability. A preoperative biopsy was usually rejected based on the fact that negative results do not exclude malignancy, that such biopsy may hamper the possibility of curative surgery because of potential seeding along the biopsy’s trajectory, that surgical morbidity and mortality are low, and also because of the high diagnostic sensitivity of the various imaging techniques. Biopsy for solid pancreatic tumors was limited to irresectable tumors, and isolated cases with suspicion of tuberculosis, lymphoma or neuroendocrine tumors. Nowadays the performance of a pancreatic biopsy is becoming essential for the correct management of solid lesions, and is useful not only to establish malignancy, but also for a better knowledge of all kind of pathologies and, thus, for better therapeutic management. In this context, endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has proven a safe technique with a low rate of complications and a diagnostic accuracy superior to other procedures, this being considered the method of choice for the study of solid pancreatic lesions. An illustrative example is the case we report in this article –a patient diagnosed of a solid, locally advanced-stage pancreatic tumor with imaging techniques (abdominal ultrasounds and EUS) under EUS-guided FNA; the procedure could establish a final diagnosis of pancreatic fusocellular sarcoma.

Key words: Endoscopic ultrasounds. Fine-needle aspiration. Pancreatic tumors. Fusocellular sarcoma.

INTRODUCTION

Endoscopic ultrasounds (EUS) has become an essential tool for the study of pancreatic diseases, and is considered nowadays the procedure of choice for the diagnosis and staging of chronic pancreatitis and of both solid and cystic pancreatic tumors (1,2).

The possibility to perform a real-time punction guided by EUS is an essential advance in the management of these patients, showing a high diagnostic accuracy (3-5) with a low rate of complications (6). In fact, indications presently accepted for the performance of pancreatic punction/biopsy include –besides cyto-histological confirmation for unresectable tumors eligible for oncological treatment, the differential diagnosis between chronic pancreatitis and pancreatic cancer, the preoperative diagnosis of pancreatic tumors, and suspicion of other pancreatic tumors, including neuroendocrine tumors, lymphomas, and pancreatic tuberculosis (7,8).

CASE REPORT

We report the case of a 73-year-old with noninsulin-dependent diabetes mellitus, and a history of renal lithi-
sis and prostate cancer (Gleason 7), under treatment with radiotherapy and hormone therapy. The patient was first admitted to the Emergency Department submitted by his general practitioner due to obstructive jaundice with choloria and acholia. The patient also had a general syndrome associated to weight loss (20 kg over the last few months) and sustained hyperglycemia. During hospitalization we confirmed the presence of high bilirubin levels (6.8 g/dL) and hypertransaminasemia (AST 101 U/L, ALT 123 U/L) with cholestasis (GGT 336 U/L, alkaline phosphatase 1079 U/L). The remaining blood parameters were normal. An abdominal ultrasonogram was performed, which detected the presence of a big heterogeneous pancreatic mass measuring 6.2 x 5.8 x 6.4 cm, compatible with a malignant pancreatic tumor; it also identified malignant retroperitoneal and liver infiltration with minimal ascites around the liver and spleen, as well as a moderate focal enlargement of the bladder. The exam also described the presence of a dilated intrahepatic bile tree and common bile duct, and an enlarged gallbladder with microlithiasis. With the suspicion of pancreatic adenocarcinoma we performed EUS using a linear probe (PENTAX EG-3870UTK), and confirmed the presence of a very big hypoechoic and irregular lesion in the head of the pancreas —fusiform in shape, extending to the neck of the pancreas (Fig. 1), infiltrating the common bile duct, portal vein, splenic vein, superior mesenteric vein and confluence (with a marked alteration in the Doppler assessment) (Fig. 2), hepatic artery and superior mesenteric artery, as well as duodenal wall. We could also identify enlarged lymph nodes at the celiac axis, peripancreatically, and at the liver hilum. In the endoscopic image we observed a huge deformation of the posterior duodenal wall, with an infiltrating ulcer measuring 3 cm, with spontaneous bleeding and an adherent clot, probably related to tumor infiltration. While performing EUS we proceeded to perform a fine-needle aspiration (FNA) of the pancreatic lesion. A pathological analysis of the sample revealed the presence of an undifferentiated malignant tumor compatible with fusocellular sarcoma, with immunohistochemistry being negative for cytokeratins, c-KIT and CD34 (thus ruling out carcinoma and GIST tumor), and positive for desmine (which directed the diagnosis towards a mesenchymal sarcomatous tumor with muscular origin). The patient evolved unfavorably with a rapid progression of disease, which proved finally fatal.

**DISCUSSION**

EUS, a technique combining endoscopic and ultrasound images, is in continuous evolution since it was first established in the 1980s. In fact, with electronic equipment it is possible to perform a vascular analysis with the corresponding Doppler options (color-Doppler, angio-Doppler and pulsed-Doppler) (9). The performance of EUS with linear devices allows guided biopsies in territories of difficult percutaneous access, like the mediastinum, perirectal region, and pancreas. These biopsies can be performed with a low rate of complications.

EUS-guided FNA is the ideal way to obtain samples from pancreatic tumors. Initial results regarding the diag-
nostic accuracy of the technique were published in 1995 by Giovannini et al. The authors published a diagnostic accuracy of 79% (10). In the following years, these results improved, mainly due to technical optimization and the materials available, reaching a diagnostic accuracy that ranges between 72 and 96% for the detection of malignancy (11-20) (Table I).

Table I. EUS-guided FNA diagnostic accuracy in the cytohistological diagnosis of solid pancreatic tumors from the most important studies published

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>n</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giovannini</td>
<td>1995</td>
<td>43</td>
<td>75</td>
<td>100</td>
<td>79</td>
</tr>
<tr>
<td>Bhutani</td>
<td>1997</td>
<td>47</td>
<td>64</td>
<td>100</td>
<td>72</td>
</tr>
<tr>
<td>Gress</td>
<td>1997</td>
<td>121</td>
<td>80</td>
<td>100</td>
<td>86</td>
</tr>
<tr>
<td>Chang</td>
<td>1997</td>
<td>44</td>
<td>92</td>
<td>100</td>
<td>95</td>
</tr>
<tr>
<td>Faigel</td>
<td>1997</td>
<td>45</td>
<td>94</td>
<td>100</td>
<td>96</td>
</tr>
<tr>
<td>Wiersem</td>
<td>1997</td>
<td>124</td>
<td>87</td>
<td>100</td>
<td>88</td>
</tr>
<tr>
<td>Williams</td>
<td>1999</td>
<td>144</td>
<td>72</td>
<td>100</td>
<td>76</td>
</tr>
<tr>
<td>Voss</td>
<td>2000</td>
<td>90</td>
<td>75</td>
<td>88</td>
<td>84</td>
</tr>
<tr>
<td>Harewood</td>
<td>2002</td>
<td>184</td>
<td>94</td>
<td>71</td>
<td>-</td>
</tr>
<tr>
<td>Raut</td>
<td>2003</td>
<td>233</td>
<td>91</td>
<td>100</td>
<td>92</td>
</tr>
<tr>
<td>Eloubeidi</td>
<td>2003</td>
<td>158</td>
<td>84</td>
<td>97</td>
<td>84</td>
</tr>
<tr>
<td>Iglesias-García</td>
<td>2007</td>
<td>62</td>
<td>84</td>
<td>100</td>
<td>90</td>
</tr>
</tbody>
</table>

In these publications, results are obtained by cytological analysis of the material obtained mainly with the standard 22-gauge needles. Nowadays the use of tru-cut needles makes it possible to obtain material for histological analysis; however, there are still some limitations with this needle, as it can only be used through the stomach, and the transduodenal approach is difficult and entails more risks for complications. With this technique, diagnostic accuracy is similar to the one previously reported for cytology (around 80%) (21-23), but provides the possibility to perform special analyses on the specimens (immunohistochemistry, molecular markers, DNA and RNA), which may help in the characterization of tumors different than adenocarcinoma, like lymphomas or metastatic tumors. However, with a modification of the FNA technique samples can be obtained with 22-gauge needles that are valid for histological analysis. Our group, in a study performed in 62 patients with pancreatic masses, by combining the study of classical cytology samples and the specimens obtained with the modified technique, reached an overall diagnostic accuracy of 90% in the evaluation of solid pancreatic masses. We thus detected pancreatic metastases from an oat-cell lung cancer and a pancreatic lymphoma (24).

In our case, the patient had a pancreatic tumor revealed by imaging techniques (abdominal ultrasounds and EUS), with some morphological characteristics different to those usually seen in a pancreatic adenocarcinoma but compatible with this diagnosis. It was guided biopsy the procedure that permitted to reach a diagnosis of fusocellular sarcoma of pancreatic origin. The pancreatic localization of fusocellular sarcomas is rare and corresponds to a small percentage of pancreatic tumors, with few cases published in the literature (25,26). For the diagnosis of this type of tumors a immunohistochemical analysis is essential to demonstrate positivity for desmine and negativity for cytokeratins (excluding the possibility of a carcinoma), c-KIT and CD34 (which excludes a GIST tumor) (27). Although prognosis in this type of tumors is unpredictable, pancreatic sarcomas seem to be highly aggressive. In our patient, the tumor had an especially aggressive progression, and the patient died a few days after diagnosis.

The performance of EUS-guided FNA has also other important clinical implications, as it can contraindicate a surgical procedure in 41% of patients, avoid the performance of other diagnostic techniques in 57% of cases, and modify the therapeutic approach in 68% of cases (28).

However, EUS-guided FNA is not only a very useful tool, able to significantly optimize the diagnosis of solid pancreatic masses, but also has a low rate of complications associated with the technique. The risk of bacteremia is very low; the risk of acute pancreatitis ranges from 1 to 2%. Other complications like bleeding or peritonitis are rare. The risk of infectious complications is particularly associated with cystic lesions, and therefore antibiotics are always recommended following pancreatic cyst aspiration (29). The largest study included 355 patients who underwent EUS-guided FNA for solid pancreatic lesions; it describes a rate of complications of only 2.5% (3 cases of abdominal pain, 2 of fever, and 3 episodes of mild acute pancreatitis). None of the patients experienced clinically significant hemorrhage, perforation, or death (30). The rate of tumoral seeding with EUS-guided fine-needle aspirations is significantly lower than with percutaneous fine-needle aspiration. In the paper published by Micames et al., in the EUS-guided FNA group the percentage of patients who developed peritoneal carcinomatosis was 2.2%, significantly lower than in the group with percutaneous-guided FNA (16.3%) (p < 0.025) (31).

In conclusion, EUS-guided FNA has become an essential tool in the evaluation of pancreatic tumors, and can be considered the technique of choice for the diagnosis and local staging of both chronic pancreatitis and different pancreatic tumors. This method is thus considered as an essential tool for the diagnostic and therapeutic algorithms of pancreatic tumors. EUS has the capability to optimize the classification of pancreatic tumors, both from the images and histological characterization it allows.
REFERENCES


